Skip to main content
. Author manuscript; available in PMC: 2023 May 9.
Published in final edited form as: J Bone Joint Surg Am. 2022 Oct 27;104(24):2153–2159. doi: 10.2106/JBJS.22.00404

TABLE I.

Rules for Using the 95% CI of the Mean Cytotoxicity to Designate a Substance as Superior or Not to LCC and as Non-Inferior or Not to HCC*

Interpretation
Investigation of superiority to LCC
 95% CI lower bound >10% cytotoxicity Superior to LCC
 95% CI upper bound <10% cytotoxicity Non-superior to LCC
 95% CI includes 10% Indeterminate (may or may not be superior to LCC)
Investigation of non-inferiority to HCC
 95% CI lower bound >90% cytotoxicity Non-inferior to HCC
 95% CI upper bound <90% cytotoxicity Inferior to HCC
 95% CI includes 90% Indeterminate (may or may not be non-inferior to HCC)
*

LCC = low-cytotoxicity control, HCC = high-cytotoxicity control.